Source link : https://www.newshealth.biz/health-news/novel-drug-fails-for-two-rare-seizure-disorders/
LOS ANGELES — The novel agent soticlestat flopped in a pair of phase III trials for rare seizure disorders, researchers reported here. Among Dravet syndrome patients in the SKYLINE trial, the median change from baseline in convulsive seizure frequency over the full treatment period was -22.16% with soticlestat and -8.64% with placebo, a nonsignificant difference […]
Author : News Health
Publish date : 2024-12-10 15:25:27
Copyright for syndicated content belongs to the linked Source.